Calcium channel blockers are inadequate for malignant hyperthermia crisis
- PMID: 22349750
- DOI: 10.1007/s00540-012-1347-0
Calcium channel blockers are inadequate for malignant hyperthermia crisis
Abstract
Purpose: Malignant hyperthermia (MH) results from disordered calcium (Ca(2+)) homeostasis in skeletal muscle during general anesthesia. Although Ca(2+) channel blockers may be given to treat the tachycardia and circulatory instability, coadministration of Ca(2+) channel blockers and dantrolene is contraindicated during MH crisis. We evaluated the effect of Ca(2+) channel blockers on Ca(2+) homeostasis and their interactions with dantrolene in human skeletal muscle.
Methods: Human skeletal muscle samples were obtained by biopsy and divided into two groups according to the results of the Ca(2+)-induced Ca(2+) release rate test. Differentiated myotubes were labeled with Fura-2, and changes in the 340/380-nm ratio were used to calculate changes in Ca(2+) concentration following nifedipine treatment in the absence or presence of dantrolene.
Results: Nifedipine induced a transient increase in the intracellular Ca(2+) concentration ([Ca(2+)](i)) in a dose-dependent manner. The half-maximal concentration (EC(50)) for nifedipine was 0.718 ± 0.329 μM in the accelerated group and 1.389 ± 0.482 μM in the nonaccelerated group (P = 0.009). The addition of 50 μM dantrolene attenuated by 15.4% the increase in [Ca(2+)](i) caused by the 0.5 μM nifedipine.
Conclusion: Ca(2+) channel blockers led to increased [Ca(2+)](i) in human skeletal muscle cells. The increase is thus scarcely affected by dantrolene treatment. Data provide a greater physiologic basis for avoiding the use of Ca(2+) channel blockers during MH crisis.
Similar articles
-
The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry.J Gen Physiol. 2009 Jan;133(1):79-91. doi: 10.1085/jgp.200810105. J Gen Physiol. 2009. PMID: 19114636 Free PMC article.
-
Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression.Biomed Res Int. 2013;2013:390493. doi: 10.1155/2013/390493. Epub 2012 Dec 5. Biomed Res Int. 2013. PMID: 23509717 Free PMC article.
-
Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.Mol Pharmacol. 2008 Apr;73(4):1203-12. doi: 10.1124/mol.107.043299. Epub 2008 Jan 2. Mol Pharmacol. 2008. PMID: 18171728 Free PMC article.
-
Malignant hyperthermia: an inherited disorder of skeletal muscle Ca+ regulation.Biosci Rep. 2001 Apr;21(2):155-68. doi: 10.1023/a:1013644107519. Biosci Rep. 2001. PMID: 11725864 Review.
-
Clinical protocol for the management of malignant hyperthermia.Rev Esp Anestesiol Reanim. 2017 Jan;64(1):32-40. doi: 10.1016/j.redar.2016.06.004. Epub 2016 Sep 12. Rev Esp Anestesiol Reanim. 2017. PMID: 27633384 Review. English, Spanish.
Cited by
-
Anesthetic Management of the Hypertensive Patient: Part II.Anesth Prog. 2018 Fall;65(3):206-213. doi: 10.2344/anpr-65-03-17. Anesth Prog. 2018. PMID: 30235430 Free PMC article. Review.
-
JSA guideline for the management of malignant hyperthermia crisis 2016.J Anesth. 2017 Apr;31(2):307-317. doi: 10.1007/s00540-016-2305-z. Epub 2017 Feb 28. J Anesth. 2017. PMID: 28246924
-
[Malignant hyperthermia].Anaesthesist. 2014 Dec;63(12):908-18. doi: 10.1007/s00101-014-2392-x. Anaesthesist. 2014. PMID: 25384957 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous